ReviewReviews in endocrine & metabolic disorders2015
LRP receptor family member associated bone disease.
Review in Reviews in endocrine & metabolic disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation.Bone research · 2026Article
- Genetic contributors to osteoporosis in pregnancy and lactation associated osteoporosis (PLO).Bone · 2026Article
- Novel Homozygous Nonsense Mutation in theJournal of clinical research in pediatric endocrinology · 2023Article
- Polymorphism of LRP4 Gene (rs9667108) among Post Menopause Women with Osteoporosis.Iranian journal of public health · 2023Article
- Interleukins, growth factors, and transcription factors are key targets for gene therapy in osteoarthritis: A scoping review.Frontiers in medicine · 2023Article
- Cholesterol-induced LRP3 downregulation promotes cartilage degeneration in osteoarthritis by targeting Syndecan-4.Nature communications · 2022Article
- Heterozygous LRP1 deficiency causes developmental dysplasia of the hip by impairing triradiate chondrocytes differentiation due to inhibition of autophagy.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis.Annals of the rheumatic diseases · 2022Article
- Management of Osteoporosis in Men: A Narrative Review.International journal of molecular sciences · 2021Review
- GATA4 regulates mesenchymal stem cells via direct transcriptional regulation of the WNT signalosome.Bone · 2021Article
- LRPs in WNT Signalling.Handbook of experimental pharmacology · 2021Review
- Current advances in regulation of bone homeostasis.FASEB bioAdvances · 2020Review
- LRP6 mediated signal transduction pathway triggered by tissue plasminogen activator acts through lipid rafts in neuroblastoma cells.Journal of cell communication and signaling · 2020Article
- Hub Proteins Involved in RAW 264.7 Macrophages Exposed to Direct Current Electric Field.International journal of molecular sciences · 2020Article
- Targeted next generation sequencing of nine osteoporosis-related genes in the Wnt signaling pathway among Chinese postmenopausal women.Endocrine · 2020Article
- LRP6-CRISPR prevents activation of hepatic stellate cells and liver fibrogenesis in rats.American journal of translational research · 2020Article
- The Regulation of Bone Metabolism and Disorders by Wnt Signaling.International journal of molecular sciences · 2019Review
- β‑catenin signalling inhibits cartilage endplate chondrocyte homeostasis in vitro.Molecular medicine reports · 2019Article
- Wnt Signaling in vascular eye diseases.Progress in retinal and eye research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A dozen years ago the identification of causal mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene involved in two rare bone disorders propelled research in the bone field in totally new directions. Since then, there have been an explosion in the number of reports that highlight the role of the Wnt/β-catenin pathway in the regulation of bone homeostasis. In this review we discuss some of the most recent reports (in the past 2 years) highlighting the involvement of the members of the LRP family (LRP5, LRP6, LRP4, and more recently LRP8) in the maintenance of bone and their implications in bone diseases. These reports include records of new single nucleotides polymorphisms (SNPs) and haplotypes that suggest variants in these genes can contribute to subtle variation in bone traits to mutations that give rise to extreme bone phenotypes. All of these serve to further support and reinforce the importance of this tightly regulated pathway in bone. Furthermore, we discuss provocative reports suggesting novel approaches through inhibitors of this pathway to treat rarer diseases such as Osteoporosis-Pseudoglioma Syndrome (OPPG), Osteogenesis Imperfecta (OI), and Sclerosteosis/Van Buchem disease. It is hoped that by understanding the role of each component of the pathway and their involvement in bone diseases that this knowledge will allow us to develop new, more effective therapeutic approaches for more common diseases such as post-menopausal osteoporosis, osteoarthritis, and rheumatoid arthritis as well as these rarer bone diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.